KaloCyte

Biotechnology · Baltimore, MD · Privately Held (backing)

Developer of a red blood cell substitute designed to support oxygen delivery in trauma care settings. KaloCyte is based in Baltimore, MD. It was valued at $24.7 million at its later-stage round in Jun 2025, the last priced event on record. It has raised $5.7 million across 1 recorded round; the latest was an accelerator round in Jan 2020.

PMV mark · valuation
$24.7M
Oct 2026
Priced at
its later-stage round
Jun 2025
Total raised
$5.7M
Last round
Accelerator/Incubator
Jan 2020
What is KaloCyte worth?
$24.7MPrivateMarketView mark · Oct 2026

Valued at $24.7M at its later-stage round, Jun 2025. Nothing has traded since.

Free account
More of KaloCyte with a free account
  • ·The complete investor list: 21 names
  • ·Watch KaloCyte: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Valuation timeline

0 priced rounds · 32 daily marks since · Sep 2026 – Oct 2026
▮▮
Markrounds hold their value until the next priced eventMark, today
log scale
Post-money values unlock with a free account.Unlock the axis

Membership and data by Private Market View

KaloCyte funding history

1 rounds
DateRoundRaisedPost-money
Jan 2020Accelerator/Incubator—▮
Unlock post-money valuations

Membership and data by Private Market View

KaloCyte valuation

KaloCyte was valued at $24.7 million at its later-stage round in Jun 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has KaloCyte raised?

KaloCyte has raised $5.7 million in total; 1 of its rounds is on record. The most recent was an accelerator round in Jan 2020.

Comparable companies

Comparable biotechnology names by valuation on PrivateMarketView: Azalea Therapeutics ($153 million), Industrial Microbes ($24 million) and Kano Therapeutics ($15 million).

How KaloCyte's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For KaloCyte, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by its last priced round. Question about this number? Full methodology →

Frequently asked about KaloCyte

What is KaloCyte worth?
KaloCyte is valued at $24.7M as of Oct 2026. Valued at $24.7M at its later-stage round, Jun 2025. Nothing has traded since.
How much has KaloCyte raised?
KaloCyte has raised $5.7M in total funding across 1 recorded rounds.
When did KaloCyte last raise?
KaloCyte last raised in Jan 2020 (Accelerator/Incubator).